Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1748-717X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity ; volume:5 ; number:1 ; day:23 ; month:11 ; year:2010 ; pages:1-7 ; date:12.2010
Radiation oncology ; 5, Heft 1 (23.11.2010), 1-7, 12.2010

Creator: Deantonio, Letizia

Contributor: Gambaro, Giuseppina
Beldì, Debora
Masini, Laura
Tunesi, Sara
Magnani, Corrado
Krengli, Marco
SpringerLink (Online service)

DOI: 10.1186/1748-717X-5-112

URN: urn:nbn:de:1111-2016072613671

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Deantonio, Letizia
Gambaro, Giuseppina
Beldì, Debora
Masini, Laura
Tunesi, Sara
Magnani, Corrado
Krengli, Marco
SpringerLink (Online service)

Other Objects (12)

$Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity$

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

$Hypofractionated radiotherapy for prostate cancer$

Hypofractionated radiotherapy for prostate cancer

$Hypofractionated radiotherapy for localized prostate cancer$

Hypofractionated radiotherapy for localized prostate cancer

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors$

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation$

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

$Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity$

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

$SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment$

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

$Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)$

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

$The Role of Hypofractionated Radiotherapy in Prostate Cancer$

The Role of Hypofractionated Radiotherapy in Prostate Cancer

$Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib$

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

$Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity$

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

$Hypofractionated radiotherapy for prostate cancer$

Hypofractionated radiotherapy for prostate cancer

$Hypofractionated radiotherapy for localized prostate cancer$

Hypofractionated radiotherapy for localized prostate cancer

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors$

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation$

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

$Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity$

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

$SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment$

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

$Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)$

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

$The Role of Hypofractionated Radiotherapy in Prostate Cancer$

The Role of Hypofractionated Radiotherapy in Prostate Cancer

$Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib$

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

$Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity$

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

$Hypofractionated radiotherapy for prostate cancer$

Hypofractionated radiotherapy for prostate cancer

$Hypofractionated radiotherapy for localized prostate cancer$

Hypofractionated radiotherapy for localized prostate cancer

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors$

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

$Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis$

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

$Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation$

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

$Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity$

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

$SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment$

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

$Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)$

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

$The Role of Hypofractionated Radiotherapy in Prostate Cancer$

The Role of Hypofractionated Radiotherapy in Prostate Cancer

$Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib$

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

Hypofractionated radiotherapy for prostate cancer

Hypofractionated radiotherapy for localized prostate cancer

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

The Role of Hypofractionated Radiotherapy in Prostate Cancer

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

Hypofractionated radiotherapy for prostate cancer

Hypofractionated radiotherapy for localized prostate cancer

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

The Role of Hypofractionated Radiotherapy in Prostate Cancer

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity

Hypofractionated radiotherapy for prostate cancer

Hypofractionated radiotherapy for localized prostate cancer

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment

Prospective comparison of hypofractionated versus normofractionated intensity-modulated radiotherapy in breast cancer: Late toxicity results of the non-inferiority KOSIMA trial (ARO2010-3)

The Role of Hypofractionated Radiotherapy in Prostate Cancer

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Related objects

Reset password